XR-NTX

DRUG6 trials

Sponsors

University of Washington, University of California, Los Angeles, Friends Research Institute, Inc., NYU Langone Health

Conditions

Alcohol Use DisorderOpiate AddictionOpioid Use Disorder (OUD)Opioid Use DisordersOpioid-use Disorder

Phase 2

Harm Reduction With Pharmacotherapy (HaRP)

CompletedNCT01932801

University of WashingtonAlcohol Use Disorder

Start: 2013-08-01End: 2019-06-30Updated: 2023-05-10

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

Active, not recruitingNCT04408313

Friends Research Institute, Inc.Opioid-use Disorder

Start: 2020-10-28End: 2026-05-31Target: 240Updated: 2026-01-26

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Active, not recruitingNCT04464980

NYU Langone HealthOpioid Use Disorder (OUD)

Start: 2021-06-08End: 2027-01-31Updated: 2025-12-15

Phase 3

Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)

CompletedNCT02110264

University of California, Los AngelesOpioid Use Disorders

Start: 2015-06-30End: 2019-05-31Updated: 2020-01-22

Long-acting Naltrexone for Pre-release Prisoners

CompletedNCT02867124

Friends Research Institute, Inc.Opiate Addiction

Start: 2017-01-01End: 2026-01-01Target: 240Updated: 2026-02-03

Phase 4

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

CompletedNCT04219540

NYU Langone HealthOpioid-use Disorder

Start: 2021-01-07End: 2025-02-28Updated: 2025-05-14

Related Papers

Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).

2025-01-201 citations

Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper

BMJ Open2024-11-012 citations

Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.

2024-04-231 citations

Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.

2021-03-1029 citations

Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.

2016-12-2019 citations

Injectable pharmacotherapy for opioid use disorders (IPOD).

2016-06-0610 citations